Keywords: Geroscience, Glucose Dysregulation, Biological Aging, Precision Prevention, Continuous Glucose Monitor
Introduction
For most of recorded human history, aging has been accepted as an inescapable feature of existence as natural as the arc of the sun. Medical science, in turn, has focused its energies on treating the diseases that accompany aging: cardiovascular disease, type 2 diabetes, neurodegeneration, cancer. Yet this approach, however sophisticated, has always been reactive. It has treated symptoms while ignoring the underlying condition. The underlying condition, this article argues, is aging itself.
The last two decades have produced a seismic reorientation in how leading scientists understand the biology of aging. the identification of the hallmarks of aging by López-Otín and colleagues (2013,2023) provided for the first time, a unifying molecular framework for the aging process, one that is characterizable, measurable, and crucially, interventional. Geroscience, the field that studies the relationship between aging and age-related disease, has demonstrated that targeting the biological mechanisms of aging simultaneously prevents or delays multiple chronic diseases. This is the longevity dividend, the idea that slowing aging is among the highest-leverage interventions available to medicine [1,2,3,4].
Running through the core of this framework is a thread that health technology researchers and metabolic medicine clinicians are increasingly pulling on: the central and outsized role of glucose dysregulation in accelerating biological aging. Sugar, or more precisely, the chronic elevation and spiking of blood glucose is not merely a risk factor for type 2 diabetes. It is a systemic biological stressor that activates multiple aging pathways simultaneously: glycation of structural proteins, generation of reactive oxygen species (ROS), stimulation of proinflammatory cytokines, impairment of mitochondrial function, and dysregulation of nutrient-sensing pathways including mTOR and AMPK. The cumulative consequences is an accelerated aging phenotype [5,6,7,8].
This article synthesizes the converging evidence from geroscience, endocrinology, and inflammation biology to make three interconnected arguments: first, that aging satisfies the criteria for classification as a disease; second, that glucose dysregulation is among the most potent and modifiable accelerants of biological aging; and third, that a precision prevention paradigm, grounded in metabolic monitoring, low-glycemic dietary protocols, and evidence-based therapeutics represents a concrete and actionable strategy for treating aging before it becomes irreversible.
Redefining Aging: From Inevitability to Pathology
The Traditional View and Its Limitation
The dominant medical framework has long treated aging as a natural process, distinct from, and upstream of, disease. In this view, diseases are discrete pathological states with identifiable causes and treatments; aging is the ambient background against which they occur. This framing has had profound consequences for medical research, clinical practice, and regulatory policy. The U.S. Food and Drug Administration (FDA), for instance, does not recognize aging as an indication for drug approval. This means that no pharmaceutical intervention can be approved specifically to slow the aging process, only to treat the individual diseases it produces [3].
This paradigm, however, is increasingly difficult to sustain in the face of molecular evidence. The canonical diseases of aging, atherosclerosis type 2 diabetes, Alzheimer’s disease, osteoporosis, and sarcopenia share common biological substrates. They arise not independently but as manifestations of the same underlying dysregulation. To treat them in isolation, without addressing the aging process that generates them, is analogous to mopping the floor without turning off the tap [1,2,3].
The Case for Ageing as a Disease
Blasgosklonny (2006,2008) was among the first to articulate a rigorous argument that aging should be classified as a disease, specifically, a quasi-programmatic hyperactivation of signaling pathways (including mTOR) that becomes pathological with age. His arguments rest on the observation that the damage associated with aging is not merely degenerative but actively driven by evolutionarily conserved growth and nutrient-sensing programs that are no longer beneficial once reproductive fitness is achieved.
Independently, Gems and de Magalhães (2021) applied the operational criteria for disease classification to aging and concluded that aging fulfills every standard definition: it is characterized by specific biochemical changes, it causes suffering and disability, it is not universal across all organisms (certain species exhibit negligible senescence), and it responds to intervention. Nuland (1994) and others have noted that what we call “natural causes” in death certificates is, in almost every case, a manifestation of advanced biological aging [7,8].
The International Classificatino of Diseases (ICD—11), released in 2022, took a notable step by including an extension code (XT9T: “Ageing-related”) that acknowledged aging as a contributing cause of disease. This represents the first formal institutional recognition that aging is a pathological process amenable to classification, and it opens the door to regulatory and research frameworks that take aging itself as a target of intervention [9].
Chronological Age vs Biological Age
A pivotal conceptual distinction that reinforces the disease model is the gap between chronological age and biological age. Chronological age is simply the number of years since birth; biological age reflects the actual state of cellular and molecular aging, which can diverge significantly from chronological age based on lifestyle, genetics, and environmental exposures. Epigenetic clocks, most notably Horvath’s DNA methylation clock (2013) and subsequent generations including GrimAge and PhenoAge provide validated tools for estimating biological age from blood samples. These clocks have shown that individuals with identical chronological ages can differ by a decade or more in biological age, and that biological age is a stronger predictor of mortality and disease than chronological age. Crucially, biological age responds to intervention. This is perhaps the most compelling evidence that aging is not a fixed biological program but a modifiable pathological process [10,11].
The Hallmarks of Aging: A Systems Biology Perspective
The landmark paper by López-Otín and colleagues (2013), subsequently updated and expanded in 2023, catalogued the molecular and cellular hallmarks that characterize the aging process. The original nine hallmarks , now expanded to twelve, provide a comprehensive map of aging biology. Understanding these hallmarks is essential both for grasping why aging constitutes a disease and for identifying where glucose dysregulation intersects with aging at the deepest levels [1,2].
The Twelve hallmarks of Aging (López-Otín et al., 2023)
- Genomic instability- accumulation of DNA damage over time
- Telomere attrition- progressive shortening of chromosomal telomeres
- Epigenetic alterations- changes in DNA methylation and histone modification patterns
- Loss of proteostasis- impaired protein folding, clearance, and recycling
- Disabled macroautophagy- reduced cellular self-cleaning capacity
- Deregulated nutrient sensing- dysregulation of IGF-1/insulin, mTOR, AMPK, and sirtuins
- Mitochondrial dysfunction- impaired energy production and increased ROS generation
- Cellular senescence- accumulation of permanently arrested, proinflammatory cells
- Stem cell exhaustion- decline in regenerative capacity
- Altered intercellular communication- dysregulated endocrine and paracrine signalling
- Chronic inflammation (Inflammaging)- low-grade systemic proinflammatory state
- Dysbiosis- disruption of the gut microbiome ecology.
Critically, these hallmarks do not operate in isolation. They form an interlocked network of positive feedback loops in which derangement of one hallmark amplifies dysfunction in others. Mitochondrial dysfunction increases ROS production, which drives genomic instability, which impairs cellular repair mechanisms, which accelerates senescence, which amplifies systemic inflammation, which further impairs mitochondrial function. This cascading, self-reinforcing character is one of the strongest arguments for treating aging as a systemic disease rather than a collection of independent organ-level pathologies [1,2].
Glucose Dysregulation as a Master Upstream Driver of Aging
Of the many environmental and lifestyle factors that accelerate biological aging, chronic glucose dysregulation, driven primarily by excessive consumption of refined sugars and processed carbohydrates occupies a uniquely central position. Unlike many aging risk factors, glucose dysregulation is both pervasive (affecting the majority of adults in modern populations) and directly mechanistically linked to a broad spectrum of aging hallmarks. It is, in effect, a master upstream driver: a single pathological state that simultaneously activates multiple aging cascades.
Advanced Glycation End-Products (AGEs) and Structural Damage
When glucose molecules are chronically elevated in the bloodstream, they undergo a spontaneous non-enzymatic reaction with proteins, lipids, and nucleic acids called the Maillard reaction, the same chemical process that browns food during cooking. The products of this reaction, advanced glycation end-products (AGEs), accumulate in tissues over time, cross-linking structural proteins, stiffening collagen and elastin, impairing vascular function, and damaging the kidneys, retina, and peripheral nerves [5].
Brownlee (2001) demonstrated in a landmark review that the unifying mechanism of diabetic complications like vascular disease, neuropathy, nephropathy, retinopathy is the overproduction of superoxide by the mitochondrial electron transport chain, driven by hyperglycemia. This same mechanism, operating at lower intensity but over longer time periods, contributes to the vascular aging phenotype observed across the general population.
Vlassara and Striker (2011) further demonstrated that dietary restriction of AGEs in animal models reduced systemic inflammation, improved insulin sensitivity, and extended health span establishing not only that AGEs from endogenous glycation but also from exogenously consumed sources (high-heat-processed foods) contribute to the aging burden. This positions diet as a direct modulator of aging rate through the AGE pathway [12].
Postprandial Glucose Spikes and Oxidative Stress
While the harms of chronic hyperglycemia are well established, emerging research has focused particular attention on postprandial glucose excursions, the acute spikes in blood glucose that follow carbohydrate-rich meals. These spikes, often reaching 140–180 mg/dL even in non-diabetic individuals consuming high-glycemic foods, generate transient but repeated bursts of oxidative stress that, over decades, produce cumulative cellular damage [13].
Ceriello and colleagues (2008) demonstrated that postprandial hyperglycemia generates higher oxidative stress than sustained chronic hyperglycemia and is independently associated with cardiovascular risk. This counterintuitive finding that spikes are more harmful than plateaus has significant implications for dietary strategy. It suggests that preventing glucose excursions through low-glycemic dietary choices, meal composition (fat and protein consumed before carbohydrates), and physical activity immediately after eating may be among the most effective strategies for reducing the aging burden of glucose [13].
Continuous glucose monitoring (CGM) technology has transformed researchers’ ability to quantify individual glycemic variability in real time. Data from CGM studies indicate that mean amplitude of glycemic excursions (MAGE) and time-above-threshold metrics correlate with oxidative stress markers, endothelial dysfunction, and inflammatory cytokine levels, all of which are independent aging accelerants [13,19].
Insulin Resistance and The Aging Feedback Loop
Chronic glucose overload drives progressive insulin resistance, a state in which peripheral tissues become increasingly insensitive to insulin’s signal to absorb glucose from the bloodstream. Insulin resistance creates a self-amplifying feedback loop: as cells resist insulin, the pancreas secretes more insulin to compensate (hyperinsulinemia), which further drives fat storage, systemic inflammation, and the progression toward overt type 2 diabetes. What is less commonly appreciated is that insulin resistance is not merely a metabolic disease risk factor; it is itself an aging accelerant [7,8].
The insulin/IGF-1 signalling (IIS) pathway is one of the most evolutionarily conserved nutrient-sensing pathways regulating lifespan across organisms from C. elegans to mammals. Reduced IIS signalling is consistently associated with extended lifespan in model organisms. Conversely, chronic hyperinsulinemia, the direct consequence of insulin resistance, maintains high IIS activation, promoting growth, anabolism, and accelerated aging. This mechanistic link between chronic sugar consumption, insulin resistance, hyperinsulinemia, and accelerated aging represents one of the strongest arguments for positioning glucose control at the center of any longevity strategy [7,8,14].
Inflammaging: The Sugar- Inflammaging- Aging Triangle
Franceschi and colleagues coined the term “inflammaging” to describe the chronic, low-grade, sterile proinflammatory state that characterizes aging. This is not the acute inflammation of infection or injury but a smoldering, systemic inflammatory activation that accelerates tissue aging, promotes neurodegeneration, atherosclerosis, insulin resistance, and cancer. Inflammaging is now recognized as a unifying feature of virtually all age-related diseases [6].
Glucose dysregulation is a primary driver of inflammaging through at least three mechanisms. First, AGEs bind to their receptor RAGE (Receptor for Advanced Glycation End-products), activating NF-κB and triggering a proinflammatory cytokine cascade including TNF-α, IL-6, and IL-1β. Second, postprandial hyperglycemia directly activates the NLRP3 inflammasome , a key innate immune sensor generating IL-1β and IL-18. Third, visceral adiposity driven by insulin resistance functions as an endocrine organ secreting proinflammatory adipokines. Together, these pathways establish glucose dysregulation as a primary upstream trigger of the inflammaging phenotype [5,6].
mTOR, AMPK, and Nutrient-Sensing Pathway Dysregulation
Among the most compelling molecular links between sugar consumption and aging is the dysregulation of nutrient-sensing pathways, particularly the mechanistic target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK). These two pathways function as biological sensors of nutrient abundance and energy status, respectively, and they act in opposition: mTOR promotes anabolism and growth when nutrients are plentiful; AMPK activates catabolic, stress-resistance, and longevity programs when energy is scarce [7,8,25].
Chronic high-carbohydrate, high-sugar diets maintain persistently elevated insulin and glucose levels, which tonically activate mTOR signalling and suppress AMPK. Blagosklonny (2012) described this as “hyperfunction theory”: aging pathology results not from cellular failure but from the excessive, age-inappropriate continued activation of growth programs that are beneficial in youth but pathological in adults. Elevated mTOR suppresses autophagy , the cellular self-cleaning process leading to the accumulation of dysfunctional proteins and organelles that drive cellular senescence. Conversely, interventions that reduce mTOR activity (rapamycin, caloric restriction, intermittent fasting) and activate AMPK (metformin, exercise, low-carbohydrate diets) consistently extend health span in animal models and show promising results in humans [7,16,17,25].
Metabolic Disease as Accelerated Aging
If glucose dysregulation accelerates the hallmarks of aging, it follows that metabolic diseases defined by chronic glucose dysregulation should manifest as phenotypes of accelerated aging. The evidence for this is compelling and convergent [1,2,5]..
Type 2 diabetes, the most advanced form of glucose dysregulation, is characterized by accelerated epigenetic aging (as measured by DNA methylation clocks), elevated markers of cellular senescence, telomere shortening, mitochondrial dysfunction, and heightened systemic inflammation, in other words, by the simultaneous acceleration of multiple aging hallmarks. Individuals with type 2 diabetes have biological ages that are, on average, five to ten years older than their chronological age, and their risk of all major age-related diseases like cardiovascular disease, dementia, cancer, kidney failure is dramatically elevated [10,11].
Critically, this relationship operates on a continuum. Prediabetes, metabolic syndrome, and even non-diabetic glycemic variability are associated with accelerated biological aging in proportion to their severity. A large body of observational evidence from CGM studies and epidemiological cohorts has demonstrated that time spent in elevated postprandial glucose ranges even within the “normal” clinical range correlates with aging biomarkers. This suggests that the threshold for metabolically significant aging acceleration lies well below the diagnostic threshold for diabetes, and that population-level metabolic health is significantly worse than clinical diabetes statistics suggest [13,19].
Zimmet and colleagues (2016) estimated that 50–70% of adults globally exhibit some degree of metabolic dysfunction, including prediabetes, insulin resistance, and central adiposity, with the majority undiagnosed. If metabolic dysfunction is both highly prevalent and an accelerant of biological aging, then population-level aging is occurring substantially faster than chronological aging rates would suggest and the global burden of age-related disease is being substantially driven by dietary sugar exposure [18].
Aging is Treatable: The Evidence Base
The most consequential implication of reclassifying aging as a disease is that it becomes a therapeutic target. An extensive and rapidly growing body of evidence demonstrates that the biological aging process can be slowed, reversed in some of its manifestations, and in multiple model organisms dramatically extended. The challenge is translating these findings into human clinical practice within an ethical, evidence-based framework [1,2,3].
Dietary Interventions: The Glycemic Lever
The most accessible and evidence-rich interventions targeting aging through glucose metabolism are dietary. Caloric restriction, the original longevity intervention, demonstrated to extend lifespan in every model organism tested from yeast to primates exerts many of its benefits through the reduction of insulin/IGF-1 signalling and mTOR activation, both of which are driven by glucose and amino acid availability. Fontana and colleagues (2010) demonstrated that long-term caloric restriction in humans produces a metabolic and endocrine profile resembling younger biological age, with reduced inflammatory markers, improved insulin sensitivity, and lower cardiovascular risk [14].
Intermittent fasting and time-restricted eating (TRE) replicate many benefits of caloric restriction through periodic glucose and insulin lowering, enhanced autophagy, and AMPK activation without requiring chronic caloric deficit. Clinical trials have demonstrated benefits on metabolic syndrome components, inflammatory markers, and biological age estimates. Low-glycemic and very-low-carbohydrate (ketogenic) diets reduce postprandial glucose excursions, lower insulin levels, and improve multiple aging-related biomarkers. An often-overlooked meal composition strategy, consuming protein and fat before carbohydrates (the “food order” approach) has been shown to blunt postprandial glucose spikes by 25–73% and represents a practical, no-cost intervention accessible to any individual [14,15].
Pharmacological Interventions
The pharmacological pipeline for aging intervention has expanded dramatically in the past decade. Several compounds originally developed for metabolic disease have demonstrated geroprotective properties:
- Metformin: The first-line pharmacological therapy for type 2 diabetes, metformin activates AMPK, suppresses mTOR, reduces systemic inflammation, and has been associated with reduced all-cause mortality and cancer risk even compared to non-diabetic controls. The Targeting Aging with Metformin (TAME) trial, led by Barzilai and colleagues, is the first FDA-approved clinical trial designed explicitly to test an intervention against aging as an endpoint [16].
- Rapamycin (Sirolimus): An mTOR inhibitor that was the first drug demonstrated to extend lifespan in aged mammals (Harrison et al., 2009), rapamycin and its derivatives are being investigated as geroprotective agents in several human trials [17].
- GLP-1 Receptor Agonists (e.g., semaglutide): Beyond their established roles in glucose management and weight reduction, GLP-1 agonists have demonstrated anti-inflammatory, cardioprotective, and neuroprotective properties, with emerging evidence of effects on aging biomarkers [20].
- Senolytics: Compounds such as dasatinib and quercetin that selectively eliminate senescent cells have shown promising results in early human trials for age-related conditions including frailty, pulmonary fibrosis, and musculoskeletal aging [20].
- NAD+ precursors (NMN, NR): Supplementation with nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) aims to restore declining NAD+ levels, supporting sirtuin activity, DNA repair, and mitochondrial function [21].
Continuous Glucose Monitoring as a Longevity Tool
Perhaps the most transformative technology in the democratization of longevity medicine is the continuous glucose monitor (CGM). Originally developed for diabetes management, CGM devices now provide real-time, minute-by-minute data on blood glucose dynamics, enabling users to observe the glycemic impact of specific foods, meal timing, stress, sleep, and exercise with unprecedented resolution [19].
In the context of aging prevention, CGM enables what might be called “glycemic feedback loops”, the ability to observe and modify behaviour based on actual metabolic response rather than population-averaged dietary guidelines. Research from Hall and colleagues using CGM in non-diabetic individuals revealed high inter-individual variability in glycemic response to identical foods, validating the need for personalized dietary guidance rather than universal prescriptions. CGM also enables the quantification of glycemic variability metrics, including time in range, time above threshold, and mean amplitude of glycemic excursions that are increasingly recognized as clinically meaningful aging biomarkers independent of mean glucose [19].
Exercise and Mitochondrial Biogenesis
Physical exercise remains the single most evidence-rich intervention for healthy aging and acts directly on multiple glucose-aging intersections. Aerobic exercise acutely lowers blood glucose through non-insulin-dependent glucose uptake in muscle; chronically, it improves insulin sensitivity, reduces visceral adiposity, and activates AMPK-driven mitochondrial biogenesis. Resistance exercise preserves skeletal muscle mass, the primary peripheral glucose sink, counteracting the sarcopenia and insulin resistance that accelerate with advancing age. Post-meal exercise of as little as 10–15 minutes has been demonstrated to reduce postprandial glucose excursions significantly, establishing simple behavioural protocols for glucose management that require no pharmacological intervention [14,15].
The Future of Longevity Medicine: Precision Prevention
The convergence of geroscience, wearable biosensor technology, and artificial intelligence creates the conditions for a new paradigm in healthcare: precision prevention. Rather than diagnosing and treating disease after it manifests a strategy that is both costly and often insufficient, precision prevention aims to identify and modify the biological processes that generate disease, before pathology becomes clinically apparent [3].
In the domain of metabolic aging, precision prevention centers on continuous metabolic monitoring coupled with individualized intervention. AI-powered analysis of CGM data, combined with self-reported dietary intake, sleep quality, physical activity, and stress metrics, enables the identification of personalized glycemic patterns, risk trajectories, and optimal intervention strategies. This is not a distant future: companies in the metabolic health and longevity space are already deploying these tools at scale [19].
The therapeutic target hierarchy in this framework is explicit: prevent postprandial glucose spikes → reduce AGE burden → suppress chronic inflammation → restore insulin sensitivity → normalize nutrient-sensing pathway activity → slow biological aging. Each step in this chain is both measurable and modifiable. This is the defining characteristic of a treatable disease [5,6,7,12,13].
The long-term vision is a healthcare system organized around aging biology rather than individual disease categories, one in which interventions are initiated in the third and fourth decades of life, not after the sixth, and in which the dominant metric of therapeutic success is biological age reduction rather than symptom suppression. The economic case for this shift is compelling: Olshansky and colleagues (2006) estimated that a two-year reduction in the biological aging rate would have greater economic value than the elimination of any single age-related disease, including cancer and heart disease [4].
Conclusion
We stand at an inflection point in the history of medicine. The tools to understand, measure, and meaningfully slow biological aging exist today. The molecular mechanisms connecting diet, glucose, inflammation, and aging have been elucidated with sufficient depth to support evidence-based intervention. The only things missing are the will to reclassify aging as the disease it is, and the infrastructure to treat it as such.
Aging is not a natural death. It is an accumulation of pathological processes, many of them driven by the cumulative metabolic consequences of modern diets dominated by defined sugars that progressively disable the body’s self-maintenance systems and generate the disease we have mistakenly treated as the primary events. Sugar is not merely bad for your waistline. At the cellular level, it is a corrosive accelerant of the aging process, triggering glycation, oxidative stress, inflammation, and the breakdown of the nutrient-sensing machinery that, when properly calibrated, enables a long and healthy life.
The imperative, then, is clear: reclassify aging, reframe prevention, and build the technological and clinical infrastructure to treat biological aging before it becomes irreversible. Glucose dysregulation offers a uniquely accessible lever for this transformation, one that can be monitored continuously, modified through diet and lifestyle, and targeted pharmacologically. The age of reactive medicine is ending. The age of longevity medicine has begun.
Reference
1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039
2. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-78. doi:10.1016/j.cell.2022.11.001
3. Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Geroscience: Linking aging to chronic disease. Cell. 2014;159(4):709-13. doi:10.1016/j.cell.2014.10.039
4. Olshansky SJ, Perry D, Miller RA, Butler RN. Pursuing the longevity dividend: Scientific goals for an aging world. Ann N Y Acad Sci. 2006;1067:11-18. doi:10.1196/annals.1354.003
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20. doi:10.1038/414813a
6. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-90. doi:10.1038/s41574-018-0059-4
7. Blagosklonny MV. Aging and immortality: Quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle. 2006;5(18):2087-102. doi:10.4161/cc.5.18.3288
8. Blagosklonny MV. Aging: ROS or TOR. Cell Cycle. 2008;7(21):3344-54. doi:10.4161/cc.7.21.6965
9. Gems D, de Magalhaes JP. The hoverfly and the wasp: A critique of the hallmarks of aging as a paradigm. Ageing Res Rev. 2021;70:101407. doi:10.1016/j.arr.2021.101407
10. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. doi:10.1186/gb-2013-14-10-r115
11. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging. 2019;11(2):303-27. doi:10.18632/aging.101684
12. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol. 2011;7(9):526-39. doi:10.1038/nrendo.2011.74
13. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57(5):1349-54. doi:10.2337/db08-0063
14. Fontana L, Partridge L, Longo VD. Extending healthy life span – from yeast to humans. Science. 2010;328(5976):321-6. doi:10.1126/science.1172539
15. Fontana L, Partridge L. Promoting health and longevity through diet: From model organisms to humans. Cell. 2015;161(1):106-18. doi:10.1016/j.cell.2015.02.020
16. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-5. doi:10.1038/nature08221
17. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-5. doi:10.1016/j.cmet.2016.05.011
18. Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies. Nat Rev Endocrinol. 2016;12(10):616-22. doi:10.1038/nrendo.2016.105
19. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079-94. doi:10.1016/j.cell.2015.11.001
20. Kirkland JL, Tchkonia T. Senolytic drugs: From discovery to translation. J Intern Med. 2020;288(5):518-36. doi:10.1111/joim.13141
21. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-71. doi:10.1016/j.tcb.2014.04.002
22. Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019;18(6):e13028. doi:10.1111/acel.13028
23. Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature. 2018;561(7721):45-56. doi:10.1038/s41586-018-0457-8
24. Kaeberlein M. Longevity and aging. F1000Res. 2021;2:221. doi:10.12688/f1000research.2-221.v1
25. Blagosklonny MV. Rapamycin and quasi-programmed aging: Four years later. Cell Cycle. 2010;9(10):1859-62. doi:10.4161/cc.9.10.11872